Search

everythinglearnresearchcommunity

for

Search:↓

The user started using a hair loss treatment regimen including 5% minoxidil spray twice daily, 1% finasteride spray once daily, microneedling weekly, and ketoconazole shampoo twice a week, experiencing significant hair shedding. The shedding is seen as a positive sign, indicating hair follicles are entering a new growth phase.

Switching from topical to oral minoxidil caused acne breakouts, leading the user to revert to topical use. Finasteride was also used, but acne was suspected to be linked to oral minoxidil.

The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.

The user is anxious about potential side effects of finasteride, particularly PFS, and is considering reinstating it for hair loss treatment. They experienced anxiety-induced side effects previously and are seeking advice on overcoming their fear of restarting finasteride.

The user experienced temple recession, shedding, and acne while on 0.5mg dutasteride, 1.25mg finasteride every other day, and 5mg oral minoxidil daily. They are considering switching treatments due to worsening symptoms and are contemplating using a topical anti-androgen like RU58841.

The user experienced significant hair regrowth using finasteride and minoxidil. They plan to switch to dutasteride for its potency after confirming their body's tolerance to DHT blockers.

A 21-year-old male is experiencing crown balding and is using RU58841, topical minoxidil, and plans to add dutasteride and oral minoxidil to his treatment. He seeks advice on increasing his treatment stack despite previous side effects like chest pain.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.